<SEC-DOCUMENT>0001193125-23-253450.txt : 20231010
<SEC-HEADER>0001193125-23-253450.hdr.sgml : 20231010
<ACCEPTANCE-DATETIME>20231010160030
ACCESSION NUMBER:		0001193125-23-253450
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20231010
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231010
DATE AS OF CHANGE:		20231010

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		231317892

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d567242d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ino="http://www.inovio.com/20231010" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-10-10_to_2023-10-10">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-10-10_to_2023-10-10">0001055726</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="ino-20231010.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-10-10_to_2023-10-10"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-10-10</xbrli:startDate> <xbrli:endDate>2023-10-10</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, DC 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-10-10_to_2023-10-10">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-10-10_to_2023-10-10" format="ixt:datemonthdayyearen">October&#160;10, 2023</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-10-10_to_2023-10-10">Inovio Pharmaceuticals, Inc.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-10-10_to_2023-10-10" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-10-10_to_2023-10-10">001-14888</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-10-10_to_2023-10-10">33-0969592</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:99%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-10-10_to_2023-10-10">660 W. Germantown Pike</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2023-10-10_to_2023-10-10">Suite 110</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-10-10_to_2023-10-10">Plymouth Meeting</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-10-10_to_2023-10-10">PA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-10-10_to_2023-10-10">19462</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices, including zip code)</span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-10-10_to_2023-10-10">(267)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-10-10_to_2023-10-10">440-4200</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-10-10_to_2023-10-10" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-10-10_to_2023-10-10" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-10-10_to_2023-10-10" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-10-10_to_2023-10-10" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-10-10_to_2023-10-10">Common Stock, $0.001 par value</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-10-10_to_2023-10-10">INO</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-10-10_to_2023-10-10" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-10-10_to_2023-10-10" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;7.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As described in Item 8.01 below, on October&#160;10, 2023, Inovio Pharmaceuticals, Inc. (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Company</span></span>&#8221;) issued a press release announcing that it has received feedback from the U.S. Food and Drug Administration (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">FDA</span></span>&#8221;) that data from the Company&#8217;s completed Phase 1/2 clinical trial of its lead product candidate <span style="white-space:nowrap">INO-3107</span> for the treatment of recurrent respiratory papillomatosis (&#8220;<span style="font-weight:bold"><span style="font-style:italic">RRP</span></span>&#8221;) can be used to support the submission of a Biologic License Application (&#8220;<span style="font-weight:bold"><span style="font-style:italic">BLA</span></span>&#8221;) for review under the FDA&#8217;s accelerated approval program. The press release is attached as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated herein by reference. The information contained in this Item 7.01, as well as the press release furnished as Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Exchange Act</span></span>&#8221;), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any of the Company&#8217;s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;10, 2023, the Company announced that it has received FDA feedback that data from the Company&#8217;s completed Phase 1/2 clinical trial of <span style="white-space:nowrap">INO-3107</span> for the treatment of RRP can be used to support the submission of a BLA for review under the FDA&#8217;s accelerated approval program. The FDA also advised that the Company will no longer be required to conduct its previously planned Phase 3 randomized, placebo-controlled trial; however, the Company will need to initiate a confirmatory clinical trial prior to BLA submission for accelerated approval and will also need to satisfy all other FDA filing requirements. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"><span style="font-weight:bold">Exhibit<br />Number</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d567242dex991.htm">Press Release, dated October&#160;10, 2023, &#8220;INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of <span style="white-space:nowrap">INO-3107</span> Can Be Used to Submit a BLA Under Accelerated Approval Program.&#8221; </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (formatted as inline XBRL).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">INOVIO PHARMACEUTICALS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: October&#160;10, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Kies</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Peter Kies</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Financial Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d567242dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of <FONT STYLE="white-space:nowrap">INO-3107</FONT> Can Be Used to
Submit a BLA Under Accelerated Approval Program </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Previously planned Phase 3 trial no longer required to support Biological License Application (BLA)
submission </I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>If approved, <FONT STYLE="white-space:nowrap">INO-3107</FONT> could potentially revolutionize treatment
options for patients with Recurrent Respiratory Papillomatosis (RRP), a debilitating rare disease caused by human papillomavirus (HPV)</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#150;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><FONT STYLE="white-space:nowrap">INO-3107</FONT> could be the first DNA medicine available in the United
States and the first commercial product for INOVIO </I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLYMOUTH MEETING, PA &#150; October&nbsp;10, 2023 &#150; INOVIO (NASDAQ:INO), a
biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from <FONT STYLE="white-space:nowrap">HPV-related</FONT> diseases, cancer, and infectious diseases, today announced that it has received
feedback from the U.S. Food and Drug Administration (FDA) that data from its completed Phase 1/2 trial of <FONT STYLE="white-space:nowrap">INO-3107</FONT> for the treatment of RRP could support INOVIO&#146;s submission of a BLA for review under the
FDA&#146;s accelerated approval program. The FDA also advised that the company&#146;s previously planned Phase 3 randomized, placebo-controlled trial would not be required to support this submission. INOVIO will be required to initiate a
confirmatory trial prior to BLA submission for accelerated approval and satisfy all other FDA filing requirements. The design of the confirmatory trial has not yet been finalized. If approved, <FONT STYLE="white-space:nowrap">INO-3107</FONT> would
be the first DNA medicine in the United States and the first INOVIO candidate to receive regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Following the recent grant of
Breakthrough Therapy Designation for <FONT STYLE="white-space:nowrap">INO-3107</FONT> for the treatment of RRP, we&#146;re grateful for the additional feedback from the FDA providing a potentially accelerated development pathway. We believe <FONT
STYLE="white-space:nowrap">INO-3107</FONT> could become a game-changing treatment option for those suffering from RRP, a serious and often <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT>
disease,&#148; said INOVIO&#146;s President and Chief Executive Officer, Dr.&nbsp;Jacqueline Shea. &#147;We&#146;re now focused on streamlining our development plan to support submission of a BLA for accelerated approval. We would like to thank the
patients and investigators who have participated in our trials to date.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I commend the FDA for recognizing the immense burden RRP puts on
patients and the critical need for a better standard of care,&#148; said the President of the Recurrent Respiratory Papillomatosis Foundation, Kim McClellan. &#147;I&#146;m thrilled by the progress being made for RRP patients who are desperate for
an alternative to surgery.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO&#146;s completed Phase 1/2 open-label, multicenter trial assessed
<FONT STYLE="white-space:nowrap">INO-3107&#146;s</FONT> safety, tolerability, immunogenicity, and efficacy in patients with <FONT STYLE="white-space:nowrap">HPV-6</FONT> and/or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HPV-11-related</FONT></FONT> RRP (NCT:04398433). The trial evaluated the reduction in the number of surgical interventions in the year following initial administration of <FONT
STYLE="white-space:nowrap">INO-3107</FONT> compared to the year prior to treatment. Patients received four doses of <FONT STYLE="white-space:nowrap">INO-3107</FONT> on Day 0, and Weeks 3, 6, and 9. Overall, 81.3% (26/32) of patients in the trial had
a decrease in surgical interventions in the year after <FONT STYLE="white-space:nowrap">INO-3107</FONT> administration compared to the prior year, including 28.1% (9/32) that required no surgical intervention during or after the dosing window.
Patients in the trial had a median range of 4 surgeries <FONT STYLE="white-space:nowrap">(2-8)</FONT> in the year prior to dosing. After dosing, there was a median decrease of 3 surgical interventions (95% confidence interval <FONT
STYLE="white-space:nowrap">-3,</FONT> <FONT STYLE="white-space:nowrap">-2).</FONT> At the outset of the study (Day 0), patients could have RRP tissue surgically removed, but any surgery performed after Day 0 during the dosing window was counted
against the efficacy endpoint. Treatment with <FONT STYLE="white-space:nowrap">INO-3107</FONT> generated a strong immune response in the trial, inducing activated CD4 T cells and activated CD8 T cells with lytic potential. <FONT
STYLE="white-space:nowrap">T-cell</FONT> responses were also observed at Week 52, indicating a persistent cellular memory response. <FONT STYLE="white-space:nowrap">INO-3107</FONT> was well tolerated by participants in the trial, resulting in mostly
<FONT STYLE="white-space:nowrap">low-grade</FONT> (Grade 1) treatment-emergent adverse effects such as injection site pain and fatigue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Data from this
Phase 1/2 trial were presented earlier this year at scientific and medical conferences, including the 2023 Annual Meeting of the American Broncho-Esophageal Association (ABEA) in May and at the European Laryngological Association&#146;s Annual
Meeting in June. Data from the trial was also published in May in the peer-reviewed journal, <I>The Laryngoscope</I>, under the title &#147;Interim Results of a Phase 1/2 Open-Label Study of <FONT STYLE="white-space:nowrap">INO-3107</FONT> for <FONT
STYLE="white-space:nowrap">HPV-6</FONT> and/or <FONT STYLE="white-space:nowrap">HPV-11&#150;Associated</FONT> RRP.&#148;<I> The Laryngoscope</I> is the official journal of the Triological Society (TRIO), the American Laryngological Association
(ALA), and the ABEA. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">INO-3107</FONT> is INOVIO&#146;s lead candidate and one of three
clinical-stage DNA medicine candidates targeting <FONT STYLE="white-space:nowrap">HPV-related</FONT> disease. INOVIO&#146;s DNA technology has been studied in twelve <FONT STYLE="white-space:nowrap">HPV-related</FONT> trials, ranging from Phase 1 to
Phase 3, involving more than 900 patients in 20 countries with a variety of <FONT STYLE="white-space:nowrap">HPV-related</FONT> diseases, including RRP, HSIL (cervical, anal and vulvar) and head and neck cancers. Shared observations in these trials
include the ability of DNA medicines to generate HPV antigen specific T cells and a persistent cellular memory response, viral clearance and lesion regression, and no anti-vector immune responses. All three
<FONT STYLE="white-space:nowrap">HPV-related</FONT> product candidates <FONT STYLE="white-space:nowrap">(INO-3107,</FONT> <FONT STYLE="white-space:nowrap">INO-3112</FONT> and <FONT STYLE="white-space:nowrap">VGX-3100)</FONT> have been well tolerated
in these trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Updated Cash Guidance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO
previously announced it expected its cash runway to fund the company&#146;s operations into the third quarter of 2025. The changes to the development plan for <FONT STYLE="white-space:nowrap">INO-3107</FONT> as a result of the FDA feedback announced
today could affect that prior guidance. The company plans to provide updated cash guidance on its third quarter earnings call scheduled to take place in November. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About RRP </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RRP is a debilitating and rare disease caused
primarily by <FONT STYLE="white-space:nowrap">HPV-6</FONT> and/or <FONT STYLE="white-space:nowrap">HPV-11.</FONT> RRP is characterized by the development of small, wart-like growths, or papillomas, in the respiratory tract. While papillomas are
generally benign, they can cause severe, life-threatening airway obstruction and respiratory complications. RRP can also significantly affect quality of life for patients by affecting the voice box, limiting the ability to speak effectively. Surgery
to remove papillomas is the standard of care for RRP; however, the papillomas often grow back because the underlying HPV infection has not been eradicated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The most widely cited U.S. epidemiology data published in 1995 estimated that there were 14,000 active cases and about 1.8 per 100,000 new cases in adults
each year. More recent pediatric epidemiology data cites a range of 0.5&#151;0.7 per 100,000 new cases in children in the U.S. each year. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT
STYLE="white-space:nowrap">INO-3107</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">INO-3107</FONT> is INOVIO&#146;s lead DNA medicine product candidate and
is being developed as a potential treatment for RRP. <FONT STYLE="white-space:nowrap">INO-3107</FONT> is designed to elicit a targeted T cell response against <FONT STYLE="white-space:nowrap">HPV-6</FONT> and
<FONT STYLE="white-space:nowrap">HPV-11,</FONT> the HPV types responsible for causing RRP among other <FONT STYLE="white-space:nowrap">HPV-related</FONT> diseases. These targeted T cells are designed to seek out and kill infected cells, with the aim
of potentially preventing or slowing the growth of new papillomas. <FONT STYLE="white-space:nowrap">INO-3107&nbsp;was</FONT> designated a Breakthrough Therapy by the FDA in September 2023. <FONT STYLE="white-space:nowrap">INO-3107</FONT> received
Orphan Drug designation from the European Commission in May 2023 and from the FDA in 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About INOVIO&#146;s DNA Medicines Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO&#146;s DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIO&#146;s proprietary investigational
medical device, CELLECTRA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>. INOVIO uses proprietary technology to design its DNA plasmids, which are small circular DNA molecules that work like software the body&#146;s cells can download to
produce specific proteins to target and fight disease. INOVIO&#146;s CELLECTRA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> delivery devices help ensure its DNA medicines enter the body&#146;s cells for optimal effect, without chemical
adjuvants or nanoparticles and without the risk of the anti-vector response seen in viral vector platforms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About INOVIO </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from
<FONT STYLE="white-space:nowrap">HPV-related</FONT> diseases, cancer, and infectious diseases. INOVIO&#146;s technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools.
For more information, visit www.inovio.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media: Jennie Willson (267) <FONT STYLE="white-space:nowrap">429-8567</FONT> <U>jennie.willson@inovio.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors: Thomas Hong (267) <FONT STYLE="white-space:nowrap">440-4298</FONT> <U>thomas.hong@inovio.com</U> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains certain forward-looking statements relating to INOVIO&#146;s business, including its plans to develop and commercialize DNA
medicines and its expectations regarding its research and development programs, including plans to initiate a confirmatory trial for <FONT STYLE="white-space:nowrap">INO-3107</FONT> instead of the previously-announced Phase 3 trial, expectations
with respect to <FONT STYLE="white-space:nowrap">INO-3107,</FONT> if approved, expectations that the updated development plan for <FONT STYLE="white-space:nowrap">INO-3107</FONT> may affect prior financial guidance, and plans for regulatory
submissions. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, clinical trials, product
development programs and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop
viable DNA medicines, INOVIO&#146;s ability to support its pipeline of DNA medicine products, the ability of INOVIO&#146;s collaborators to attain development and commercial milestones for products INOVIO licenses and product sales that will enable
INOVIO to receive future payments and royalties, the adequacy of INOVIO&#146;s capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by INOVIO or its collaborators, including
alternatives that may be more efficacious or cost effective than any therapy or treatment that INOVIO and its collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will
provide INOVIO with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and
whether INOVIO can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of INOVIO&#146;s technology by potential corporate or other partners or
collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in INOVIO&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022, its
Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2023, and other filings INOVIO makes from time to time with the Securities and Exchange Commission. There can be no assurance that any product
candidate in INOVIO&#146;s pipeline will be successfully developed, manufactured, or commercialized, that the results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking
information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and INOVIO undertakes no obligation to update or revise these statements, except as may be required by law. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ino-20231010.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 10/10/2023 10:37:33 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:ino="http://www.inovio.com/20231010"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.inovio.com/20231010"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20231010_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20231010_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ino-20231010_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 10/10/2023 10:37:33 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ino-20231010_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 10/10/2023 10:37:33 PM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ino-20231010.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139810376964448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 10, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001055726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 10,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Inovio Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0969592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">660 W. Germantown Pike<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Plymouth Meeting<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(267)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-4200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>d567242d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ino-20231010.xsd" xlink:type="simple"/>
    <context id="duration_2023-10-10_to_2023-10-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2023-10-10</startDate>
            <endDate>2023-10-10</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2023-10-10_to_2023-10-10">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-10-10_to_2023-10-10"
      id="Hidden_dei_EntityCentralIndexKey">0001055726</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-10-10_to_2023-10-10">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-10-10_to_2023-10-10">2023-10-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-10-10_to_2023-10-10">Inovio Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-10-10_to_2023-10-10">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-10-10_to_2023-10-10">001-14888</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-10-10_to_2023-10-10">33-0969592</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-10-10_to_2023-10-10">660 W. Germantown Pike</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-10-10_to_2023-10-10">Suite 110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-10-10_to_2023-10-10">Plymouth Meeting</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-10-10_to_2023-10-10">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-10-10_to_2023-10-10">19462</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-10-10_to_2023-10-10">(267)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-10-10_to_2023-10-10">440-4200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-10-10_to_2023-10-10">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-10-10_to_2023-10-10">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-10-10_to_2023-10-10">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-10-10_to_2023-10-10">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-10-10_to_2023-10-10">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-10-10_to_2023-10-10">INO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-10-10_to_2023-10-10">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-10-10_to_2023-10-10">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M> \^>Q\ETWLJ.?]74_P$4$L#!!0    (  Z 2E>7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ #H!*5QPX9>H_ 0
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M 5!+ 0(4 Q0    (  Z 2E<'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ #H!*5[PD(0GM    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ #H!*5YE<G",0!@  G"<  !,              ( !RP$  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    "  .@$I7R\S;A6D$   X$0  &
M        @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ #H!*5Y^@&_"Q @  X@P   T              ( !JPP  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    "  .@$I7EXJ[',     3 @  "P
M@ &'#P  7W)E;',O+G)E;'-02P$"% ,4    "  .@$I7'#AEZC\!   \ @
M#P              @ %P$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M#H!*5R0>FZ*M    ^ $  !H              ( !W!$  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ #H!*5V60>9(9 0  SP,  !,
M             ( !P1(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D
,"0 ^ @  "Q0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d567242d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d567242d8k.htm">d567242d8k.htm</File>
    <File>ino-20231010.xsd</File>
    <File>ino-20231010_lab.xml</File>
    <File>ino-20231010_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d567242d8k.htm": {
   "nsprefix": "ino",
   "nsuri": "http://www.inovio.com/20231010",
   "dts": {
    "inline": {
     "local": [
      "d567242d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "ino-20231010.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ino-20231010_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ino-20231010_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2022": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 23
   },
   "report": {
    "R1": {
     "role": "http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2023-10-10_to_2023-10-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d567242d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2023-10-10_to_2023-10-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d567242d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentType",
     "presentation": [
      "http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.inovio.com//20231010/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001193125-23-253450-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-253450-xbrl.zip
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MV.@/-LYE2%K28$O22J [I:.CD_+Q/'W%&<Y(UF,2+!=3<(UJ7%-&XV L8BQ
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M ELZ6KA?#\C_E$# '!)221ZI'RVH4'RC"KME\X_M@E7+[>O-;VZ_^1DF*YP
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M37$QULP'/8ZN%T'8S**$DB.+A>%2AG/(L(4\09]O!C*\2$9+2HO1N=@3OD:
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MPK0_ZPA7W)^XT_MYY<+88AV3)J$M;SSX]Z1*W%*"AGIB+=GY[IZ/</;CJ]>
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MU^P2'UH+NX>-W\'?[D?Z^GU7( TJ7U8<X:,]R89:Q%UZ$0 6NW]RJZ1WK\B
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MYU]J:41*=G'R*[[D_R+3OP%02P,$%     @ #H!*5U?_V"L^ P  10L  !
M  !I;F\M,C R,S$P,3 N>'-DO5;;;MLX$'TOT'^8ZJD+K$3)1MI&B%-TFP8(
MD&8+-RWZ5M#2V"&6(K4DE<1_WR$E.;(3NTZR6,. *<Z<PS,7CGST_K:2<(W&
M"JTF49:D$: J="G48A(U-N:V$")Z?_SRQ=&K.(:3T[,+B.'*N=KFC-W<W"3E
M7"BK9>.(P2:%KAC$<>__\?(;?&_9<YBB1&X1*FX=&OBK$;+,1^EHE&7IN^3-
M$&:0>SXHN<,<LI31ESS'M,S';_/Q&+Y\AD^!1\&EJ' (UO72B,65@]?%'Q!0
M)UHIE!*7<"H45X7@$K[VFO^$,U4D\$%*F'J8):$6S3662<=Z:\O<%E=8\9<O
M "ACRN:**)MJ$OE4=)FXG1F9:+-@I3/,+6MDY!23%QI11 /H[W'W,%0*;[$K
MX)S;60#U%I^?T0 AE%X[A9ZOA0X%\CG)TBP=>)<H5MY!C\4B6>AK1H9-9F\7
M#T<P2M,QHWYPE&0<0*10_^Q >/.,6F-XR#W(S3@ LL/#0Q:L&Y)*MQY!QW[
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MN4IY!^X\=@$WB[4_\D[9=ERWVY>KO\)L\PYW.\.[WFZULX8>?P%02P,$%
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MR]B/_J;+^O<XS0JO813,IDR#L!.)-@8&U8:&(*T$JA3F?<OF;%0-@+47Q_<
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M4FJ@1>)ZA/]8LXF'K>;[5K-)^O?D)H\CR(AEL"N6\[5BTYDA/R0_DEQU+84
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M-#)D.&LN:'1M4$L! A0#%     @ #H!*5PV\@5$Z%@  F$D  !$
M     ( !-1$  &0U-C<R-#)D97@Y.3$N:'1M4$L! A0#%     @ #H!*5U?_
MV"L^ P  10L  !               ( !GB<  &EN;RTR,#(S,3 Q,"YX<V10
M2P$"% ,4    "  .@$I75Q7$[GH&  "[1@  %               @ $**P
M:6YO+3(P,C,Q,#$P7VQA8BYX;6Q02P$"% ,4    "  .@$I7O!WA"+T$   \
M+   %               @ &V,0  :6YO+3(P,C,Q,#$P7W!R92YX;6Q02P4&
2      4 !0 ] 0  I38

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
